Compare Novartis AG (NVS) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs PayPal Holdings, Inc. — how do they compare? Novartis AG trades at $143.26 (market cap $268.57B), while PayPal Holdings, Inc. trades at $55.37 (market cap $47.07B). The key difference: Novartis AG is far larger — about 5.7× PayPal Holdings, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and PayPal Holdings, Inc. for 106 Days on average.
| NVS | PYPL | |
|---|---|---|
Market Cap | $268.57B | $47.07B |
Volume | 1,532,573 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $168.62 | $75.75 |
52-Week Low | $121.80 | $39.08 |
Typical Hold Time | 82 Days | 106 Days |
Enterprise Value | $309.89B | $49.21B |
Dividend Yield | 3.31% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
PayPal (PYPL) trades at $54.95, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a 14.36% net income margin and 24.5% ROE, while recent earnings beats in Q1 and Q2 2026 and a new Meta partnership for AI-powered checkout signal positive momentum. Cash flow remains robust with $1.53B net cash flow in 2025.
PYPL presents a value opportunity with a low P/E of 10.4, but faces risks from competitive pressures in digital payments and slowing branded checkout growth. Wall Street sentiment is mixed with 35.71% buy ratings, yet the stock's current discount to historical highs and cost-cutting initiatives under new CEO Enrique Lores offer potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
